Epidermal growth factor-like protein 7 (EGFL7) mRNA (EGFL7 mRNA)

Epidermal growth factor-like protein 7 (EGFL7) mRNA encodes a secreted protein, also known as VE-statin, which is a critical regulator of vascular development and endothelial cell behavior (UniProt Q9UHF1; NCBI Gene ID: 51162). It is predominantly expressed in the vascular endothelium during embryogenesis and in adult tissues undergoing active angiogenesis, such as healing wounds or growing tumors (Parker et al., Nature, 2004). EGFL7 functions by modulating the Notch signaling pathway and interacting with the extracellular matrix to guide proper blood vessel tubulogenesis and patterning (Schmidt et al., Blood, 2009). In oncology, EGFL7 mRNA is frequently overexpressed in various solid tumors, including hepatocellular carcinoma, colorectal cancer, and breast cancer, where it promotes tumor neoangiogenesis and facilitates metastasis (Wu et al., BMC Cancer, 2009). High levels of EGFL7 mRNA are often correlated with increased microvessel density and poor patient prognosis in clinical settings (Shen et al., Medical Oncology, 2013). Therapeutic targeting of EGFL7 mRNA using small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) aims to silence the expression of this pro-angiogenic factor at the source, thereby inhibiting tumor growth and potentially enhancing the efficacy of anti-VEGF therapies (Diaz et al., Expert Opinion on Therapeutic Targets, 2013). While clinical development has historically focused on monoclonal antibodies like parsatuzumab that target the EGFL7 protein, mRNA-based strategies represent a potent alternative for achieving sustained suppression of EGFL7-mediated signaling (ClinicalTrials.gov NCT01121536).

Other names

VE-statin mRNAZNEU1 mRNANotch-like protein mRNAVascular endothelial-statin mRNA

RNA interference (siRNA-mediated degradation) and antisense-mediated translation inhibition of EGFL7 protein synthesis.